Abstract
Introduction
Driven by the need to improve R&D productivity and efficiency and the desire
to access untapped markets, global pharmaceutical companies have increasingly
offshored and outsourced operations to CROs in China and India. A wide array
of factors, however, can dictate whether such a move is successful; in this
report, we examine the myriad potential savings and costs that can contribute
to the success or failure of outsourced drug discovery tasks.
Get the Answers You Need to Shape Your Strategy
- Global pharmaceutical companies (GPCs) are increasingly outsourcing
early-stage drug discovery to China and India. What market factors are
driving this outsourcing trend? What benefits beyond the obvious cost savings
might a company reap through outsourcing?
- Outsourcing may not meet a company' s expectations of higher productivity.
What complicating factors might emerge that could undermine anticipated
productivity and savings? How might companies plan their strategies to
compensate for these complications?
- While IP protection in China and India is improving, with both countries
now bound by the WTO' s IP rules, GPCs continue to face IP hurdles. What
challenges might GPCs face in resolving conflicts between local and
international law regarding patents?
- China and India are both attractive venues for offshoring and outsourcing.
Also, Indian generics companies will eventually compete in the global
innovative drug market. What are the comparative strengths and weaknesses
of companies in China and India for these tasks and operations? How might
these factors influence a GPC' s decision to do business in either of these two
countries?
Scope
- Rationale for outsourcing: primary reasons behind the decision to
outsource various functions.
- Hidden costs of outsourcing: overview of factors that can delay or
derail an outsourced project.
- Intellectual property protection: local conditions and IP laws in
China and India.
- Business environment and infrastructure: market conditions in China
and India for the pharmaceutical and biotech industries.
- Outsourcing business models: overview of four major business models
in India and China for companies and institutions specializing in outsourcing,
with special attention paid to the CRO industry.
- Market outlook the future of outsourcing drug discovery to China
and India.
Companies Mentioned in This Spectrum Report
- Accutest India
- Ace Biomed
- Advinus
- Albany Molecular Research India
- Allist Pharmaceutical Technology
- Ashco Contract Research Center
- AstraZeneca
- Aurigene Discovery Technologies
- Avra Laboratories
- Bicoll Biotechnology
- Boehringer Ingelheim
- Charles River Laboratories
- Clintox Bioservices
- Covance
- Dr. Reddy' s Laboratories
- DuPont
- Eli Lilly
- Evolva
- GlaxoSmithKline
- GVK Biosciences
- HD Biosciences
- Indian Institute of Chemical Technology
- Intox
- Jubilant Biosys
- Medicilon
- Newsummit Biopharma
- Nicholas Piramal
- Novartis
- Nycomed
- Pfizer
- Pharmacopeia
- Ranbaxy
- RCC Laboratories
- Reliance Biosciences
- Roche
- Sai Advantium
- Shanghai Ambrosia Pharmaceutical
- Shanghai ChemExplorer
- Shanghai ChemPartner
- Shanghai Fuchun Zhongnan Biotech
- Shanghai Fudan-Zhangjiang BioPharmaceutical
- Shanghai Genomics
- Shanghai Institute of Materia Medicia
- Sundia MediTech
- Sun Pharmaceuticals
- Suven Life Sciences
- Syngene
- United Pharma Tech
- WuXi PharmaTech
- Wyeth
- Zhejiang Huahai Pharmaceutical
View Cart
